Idera Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease Program

Published: Mar 11, 2013

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2012.

“During the past year, Idera has demonstrated promising clinical activity for the use of Toll-like Receptor antagonists as a novel approach for the potential treatment of autoimmune diseases,” said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer.

Back to news